Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells

Immunology

Volumn 94, Issue 4, 1998, Pages 569-574

  Wagelie Steffen, A L ^a   Hartmann, K ^a,b   Vliagoftis, H ^a   Metcalfe, D D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b German Research Foundation

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD95; CELLS, CULTURED; COCULTURE TECHNIQUES; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0031877419     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1998.00559.x     Document Type: Article

References (43)

1. IWAI K., MIYAWAKI T., TAKIZAWA T. et al. (1994) Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84, 1201.
2. HAHNE M., RENNO T., SCHROETER M. et al. (1996) Activated B cells express functional Fas ligand. Eur J Immunol 26, 721.
3. EISCHEN C.M., SCHILLING J.D., LYNCH D.H., KRAMMER P.M. & LEIBSON P.J. (1996) Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 156, 2693.
4. BADLEY A.D., M.C.ELHINNEY J.A., LEIBSON P.J., LYNCH D.H., ALDERSON M.R. & PAYA C.V. (1996) Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 70, 199.
5. LILES W.C., KIENER P.A., LEDBETTER J.A., ARUFTO A. & KLEBANOFF S.J. (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184, 429.
6. Suss G. & SHORTMAN K. (1996) A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 183, 1789.
7. YONEHARA S., NISHIMURA Y., KISHII S. et al. (1994) Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol 6, 1849.
8. ALDERSON M.R., TOUGH T.W., DAVIS-SMITH T. et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181, 71.
9. BELLGRAU D., GOLD D., SELAWRY H., MOORE J., FRANZUSOFF A. & DUKE R.C. (1995) A role for CD95 ligand in preventing graft rejection. Nature 377, 630.
10. GRIFFITH T.S., BRUNNER T., FLHTCHER S.M., GREEN D.R. & FERGUSON T.A. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189.
11. Ju S.T., Cui H., PANKA D.J., ETTINGER R. & MARSHAK-ROTHSTEIN A. (1994) Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 91, 4185.
12. COHEN P.L. & EISENBERG R.A. (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9, 243.
13. HARTMANN K., WAGELIE-STEFFEN A.L., VON STEBUT E. & METCALFE D.D. (1997) Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol 159, 4006.
14. 2+-independent T cell-mediated cytotoxicity. J Exp Med 177, 195.
15. RAZIN E., IHLE J.N., SELDIN D. et al. (1984) IL-3: a differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol 132, 1479.
16. ARORA N., MIN K.-U., COSTA J.J. & METCALFE D.D. (1993) Immortalization of mouse bone marrow-derived mast cells with Ad12-SV40 virus. Int Arch Allergy Appl Immunol 100, 319.
17. TSAI M., HUNT J., ARM J.P., LONDON C., GURISH M. & GALLI S.J. (1996) The C1. MC/C57.1 (C57) mouse mast cell line is of BALB/c origin and is tumorigenic in BALB/c mice. FASEB J 10, A1218.
18. CHOMCZYNSKI P. & SACCHI N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156.
19. TAKAHASHI T., TANAKA M., INAZAWA J., ABE T., SUDA T. & NAGATA S. (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6, 1567.
20. RUMSAENG V., VLIAGOFTIS H., OH C.K. & METCALFE D.D. (1997) Lymphotactin gene expression in mast cells following Fcε receptor l aggregation. J Immunol 158, 1353.
21. PRUSSIN C. & METCALFE D.D. (1995) Detection of intracyto-plasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Meth 188, 117.
22. KAYAGAKI N., KAWASAKI A., EBAIA T. et al. (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182, 1777.
23. HORAN P.K. & SEZAK S.E. (1989) Cell-mediated cytotoxicity. A highly sensitive and informative flow cytometric assay. J Immunol Meth 117, 205.
24. SARIN A., WILLIAMS M.S., ALEXANDER-MILLER J.A., BERZOFSKY C.M., ZACHARCHUK C.M. & HENKART P. (1997) Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity 6, 209.
25. TSAI M., TAKEISHI T., THOMPSON H. et al. (1991) Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand stem cell factor. Proc Natl Acad Sci USA 88, 6382.
26. SUDA T., TAKAHASHI T., GOLSTEIN P. & NAGATA S. (1993) Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75, 1169.
27. HAHNE M., PEITSCH M.C., IRMLER M. et al. (1995) Characterization of the non-functional Fas ligand of gld mice, Int Immunol 7, 1381.
28. LYNCH D.L., WATSON M.L., ALDERSON M.R. et al (1994) The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1, 131.
29. LYNCH D.L., RAMSDELL F. & ALDERSON M.R. (1995) Fas and FasL in the homeostatic regulation of immune responses [see comments]. Immunol Today 16, 569.
30. LOWIN B., HAHNE M., MATTMANN C. & TSCHOPP J. (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650.
31. KAGI D., VIGNAUX B., LEDERMAN B. et al. (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528.
32. DHEIN J., WALCZAK H., BAUMIER C., DEBATIN K.-M. & KRAMMER P.H. (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438.
33. BRUNNER T., MOGIL R.J., LA FACE D. et al. (1995) Cell-autonomous Fas (CD95)/Fas ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441.
34. Ju S.T., PANKA D.J., CUI H. et al. (1995) Fas (CD 95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444.
35. GORDON J.R. & GALLI S.J. (1990) Mast cells as a source of preformed and immunologically inducible TNF-alpha/cachetin. Nature 346, 274.
36. STEFFEN M., ABBOUD M., POTTER G.K., YUNG Y.P. & MOORE M.A.S. (1989) Presence of tumor necrosis factor or a related factor in human basophil/mast cells. Immunology 66, 445.
37. SUDA T., TANAKA M., MIWA K. & NAGATA S. (1996) Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 157, 3918.
38. TANAKA M., SUDA T., TAKAHASHI T. & NAGATA S. (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14, 1129.
39. MARIANI S.M., MATIBA B., BAUMLER C. & KRAMMER P.H. (1995) Regulation of cell surface APO-1/Fas (CD 95) ligand expression by metalloproteases. Eur J Immunol 25, 2303.
40. KANEDA R., IWABUCHI K. & ONOE K. (1997) Dissociation of Fas-mediated cytotoxicity and FasL expression in a cytotoxic CD4+ T-cell clone. Comparative analysis of Fas-mediated cytotoxicity between a T-hybridoma and a T-cell clone. Immunol Lett 55, 53.
41. GLASS A., WALSH C.M., LYNCH D.H. & CLARK W.R. (1996) Regulation of Fas lytic pathway in cloned CTL. J Immunol 156, 3638.
42. VIARD I., LIMAT A., SCHROTER M. et al. (1997) Expression of Fas ligand on human keratinocytes in vitro and in vivo. J Invest Dermatol 108, 569.
43. FODINGER M., FRITSCH G., WINKLER K. et al. (1994) Origin of human mast cells: development from transplanted hematopoietic stem cells after allogenic bone marrow transplantation. Blood 84, 2954.